[go: up one dir, main page]

WO2002068627A3 - Vector constucts - Google Patents

Vector constucts Download PDF

Info

Publication number
WO2002068627A3
WO2002068627A3 PCT/US2002/005280 US0205280W WO02068627A3 WO 2002068627 A3 WO2002068627 A3 WO 2002068627A3 US 0205280 W US0205280 W US 0205280W WO 02068627 A3 WO02068627 A3 WO 02068627A3
Authority
WO
WIPO (PCT)
Prior art keywords
vector
constucts
nonspecific
minimization
constructs
Prior art date
Application number
PCT/US2002/005280
Other languages
French (fr)
Other versions
WO2002068627A2 (en
Inventor
Mario Gorziglia
Paul L Hallenbeck
Michael Kaleko
Lori Clarke
Sandrina Phipps
John Leonard Jakubczak
Original Assignee
Novartis Ag
Mario Gorziglia
Paul L Hallenbeck
Michael Kaleko
Lori Clarke
Sandrina Phipps
John Leonard Jakubczak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Mario Gorziglia, Paul L Hallenbeck, Michael Kaleko, Lori Clarke, Sandrina Phipps, John Leonard Jakubczak filed Critical Novartis Ag
Priority to IL15242302A priority Critical patent/IL152423A0/en
Priority to EP02721113A priority patent/EP1377672A2/en
Priority to JP2002568722A priority patent/JP2004536572A/en
Priority to CA002439185A priority patent/CA2439185A1/en
Publication of WO2002068627A2 publication Critical patent/WO2002068627A2/en
Publication of WO2002068627A3 publication Critical patent/WO2002068627A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides novel viral vectors and methods useful for the minimization of leaky gene expression, and, in particular, of nonspecific transcriptional read-through of genes. Such constructs may be obtained by the insertion of an insulating sequence into a vector construct, such as for example a termination signal sequence upstream of the transcription initiation site of the respective transcription unit.
PCT/US2002/005280 2001-02-23 2002-02-22 Vector constucts WO2002068627A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL15242302A IL152423A0 (en) 2001-02-23 2002-02-22 Novel vector constructs
EP02721113A EP1377672A2 (en) 2001-02-23 2002-02-22 Vector constructs
JP2002568722A JP2004536572A (en) 2001-02-23 2002-02-22 New vector construct
CA002439185A CA2439185A1 (en) 2001-02-23 2002-02-22 Vector constructs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27088501P 2001-02-23 2001-02-23
US60/270,885 2001-02-23

Publications (2)

Publication Number Publication Date
WO2002068627A2 WO2002068627A2 (en) 2002-09-06
WO2002068627A3 true WO2002068627A3 (en) 2003-06-12

Family

ID=23033246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005280 WO2002068627A2 (en) 2001-02-23 2002-02-22 Vector constucts

Country Status (6)

Country Link
US (1) US7109029B2 (en)
EP (1) EP1377672A2 (en)
JP (1) JP2004536572A (en)
CA (1) CA2439185A1 (en)
IL (1) IL152423A0 (en)
WO (1) WO2002068627A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911200B2 (en) * 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
IL152423A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel vector constructs
CN1195056C (en) * 2001-07-12 2005-03-30 钱其军 Recombined virus for specific proliferation and high efficiency expression of anti-cancer gene in tumor cells and its constitution method
US7364727B2 (en) * 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
NZ540471A (en) * 2002-12-18 2008-07-31 Chromagenics Bv A method for improving protein production
AU2003290453A1 (en) * 2002-12-20 2004-07-14 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
AU2003265873A1 (en) * 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
SI1809750T1 (en) * 2004-11-08 2012-08-31 Chromagenics Bv Selection of host cells expressing protein at high levels
US20100136616A1 (en) * 2004-11-08 2010-06-03 Chromagenics B.V. Selection of Host Cells Expressing Protein at High Levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
ES2304281B1 (en) * 2006-02-01 2009-08-12 Dnatrix Inc. ADENOVIRUS ONCOLITICOS FOR THE TREATMENT OF CANCER.
WO2007103825A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus
US20080044378A1 (en) * 2006-05-15 2008-02-21 Introgen Therapeutics, Inc. Methods and Compositions for Protein Production Using Adenoviral Vectors
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
WO2009007980A1 (en) * 2007-07-11 2009-01-15 Yeda Research And Development Co. Ltd. Nucleic acid construct systems capable of diagnosing or treating a cell state
ES2385251B1 (en) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge ONCOLYTIC ADENOVIRUSES FOR THE TREATMENT OF CANCER.
TWI391486B (en) * 2009-10-20 2013-04-01 Taipei Veterans General Hospital A novel promoter and viral vector containing the same
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
WO2019157447A1 (en) 2018-02-12 2019-08-15 Trustees Of Tufts College Cd59 for inhibiting inflammasome activation
MX2024006087A (en) 2021-11-19 2024-05-30 Janssen Biotech Inc METHOD FOR TREATING GEOGRAPHIC ATROPHY WITH A GENE THERAPY VECTOR THAT EXPRESSES SOLUBLE CD59.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031286A1 (en) * 1998-11-20 2000-06-02 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
WO2001083796A2 (en) * 2000-05-03 2001-11-08 University Of Washington Adenoviral vectors for tumor specific gene expression and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL9001828A (en) 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst METHOD FOR CHANGING THE CELL, TISSUE, OR HOST TRPISM OF A MICRO-ORGANISM; SO OBTAINED RECOMBINED MICROORGANISM AND ITS APPLICATION IN MEDICINE AND VETERINARY.
US6013638A (en) * 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0689447B1 (en) 1993-02-16 1999-04-07 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6057299A (en) 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
ATE445705T1 (en) 1995-06-15 2009-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUSES FOR GENE THERAPY
FR2735789B1 (en) * 1995-06-23 1997-07-25 Centre Nat Rech Scient RECOMBINANT ADENOVIRUSES, THEIR USE FOR PREPARING AVA, COMPLEMENTARY CELL LINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
US5853716A (en) 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU2557097A (en) 1996-04-17 1997-11-07 Board Of Regents, The University Of Texas System Enhanced expression of transgenes
US20010046965A1 (en) * 1996-05-31 2001-11-29 David Ayares Adenovirus E1-complementing cell lines
AU3212197A (en) 1996-06-20 1998-01-07 Salk Institute For Biological Studies, The Modular assembly retroviral vectors and uses thereof
AU4592697A (en) 1996-09-24 1998-04-17 Dana-Farber Cancer Institute Method of targeting malignant cells using an e2f responsive promoter
WO1998027207A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Recombinase-activatable aav packaging cassettes for use in the production of aav vectors
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
AU744725B2 (en) 1997-03-03 2002-02-28 Cold Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US6432700B1 (en) 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1998039467A2 (en) 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
EP1002103B1 (en) 1997-08-04 2007-10-17 Cell Genesys, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
EP1034267A1 (en) 1997-12-04 2000-09-13 Genzyme Corporation Compositions and methods for inducing gene expression
US6436694B1 (en) * 1998-01-09 2002-08-20 Cubist Pharmaceuticals, Inc. Regulable gene expression in gram-positive bacteria
ATE517999T1 (en) 1998-04-24 2011-08-15 Onyx Pharma Inc ADENOVIRAL VECTORS FOR THE TREATMENT OF THE DISEASES
CN1301169A (en) 1998-05-15 2001-06-27 昂尼克斯药物公司 Adenovirus-chemotherapeutic combination for treating cancer
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU6497799A (en) 1998-10-15 2000-05-01 Canji, Inc. Methods and compositions to induce antitumor response
WO2000026395A2 (en) * 1998-11-02 2000-05-11 University Of Saskatchewan Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
AU2344100A (en) 1998-11-18 2000-06-05 Canji, Inc. Viral vectors with late transgene expression
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
AU761567B2 (en) 1999-02-04 2003-06-05 Geron Corporation Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer
GB9902919D0 (en) 1999-02-09 1999-03-31 Isis Innovation Modulator of inflammation
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
WO2000067576A1 (en) 1999-05-12 2000-11-16 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
NZ515582A (en) 1999-05-17 2003-11-28 Crucell Holland B Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
WO2001002540A2 (en) 1999-07-02 2001-01-11 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
US7589069B1 (en) 1999-07-12 2009-09-15 Saint Louis University Replication-competent anti-cancer vectors
WO2001023004A1 (en) 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Replication selective adenoviruses for use in cancer therapy
WO2001036650A2 (en) 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AU4370401A (en) 2000-03-24 2001-10-08 Cell Genesys Inc Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
JP2004511203A (en) 2000-03-24 2004-04-15 セル　ジェネシス　インコーポレーティッド A cell-specific adenovirus vector containing an internal ribosome access site
IL152423A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel vector constructs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031286A1 (en) * 1998-11-20 2000-06-02 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
WO2001083796A2 (en) * 2000-05-03 2001-11-08 University Of Washington Adenoviral vectors for tumor specific gene expression and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEINWAERDER D S ET AL: "INSULATION FROM VIRAL TRANSCRIPTIONAL REGULATORY ELEMENTS IMPROVES INDUCIBLE TRANSGENE EXPRESSION FROM ADENOVIRUS VECTORS IN VITRO ANDIN VIVO", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 7, April 2000 (2000-04-01), pages 556 - 567, XP008000870, ISSN: 0969-7128 *
VASSAUX G ET AL: "INSULATION OF A CONDITIONALLY EXPRESSED TRANSGENE IN AN ADENOVIRAL VECTOR", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 6, June 1999 (1999-06-01), pages 1192 - 1197, XP008000930, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
IL152423A0 (en) 2003-05-29
EP1377672A2 (en) 2004-01-07
CA2439185A1 (en) 2002-09-06
JP2004536572A (en) 2004-12-09
WO2002068627A2 (en) 2002-09-06
US20030104624A1 (en) 2003-06-05
US7109029B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
WO2002068627A3 (en) Vector constucts
WO2001047543A3 (en) Activation and inhibition of the immune system
AU2002365811A1 (en) Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
WO2003020879A3 (en) Cells and methods for propagating adenoviral vectors
WO2002037796A3 (en) Method and system for determining the popularity of a subject
WO2007075626A3 (en) Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
WO2005062937A3 (en) Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
WO2003032286A3 (en) Method and apparatus for luminance compensation for emissive displays
WO2002038738A3 (en) Chimeric molecules to modulate gene expression
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
WO2001062892A3 (en) Method for ligating nucleic acids and molecular cloning
WO2004022586A3 (en) Tubulysin biosynthesis gene
WO2004093808A3 (en) Novel tumor-associated antigens
WO2004067710A3 (en) Compositions and methods for tissue specific targeting of lentivirus vectors
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
WO2002074807A3 (en) Chimpanzee erythropoietin (chepo) - immunoadhesins
WO2002100998A3 (en) Method for generating diversity
WO2004018630A3 (en) Recombinant double-stranded rna phages and uses thereof
WO2003000893A3 (en) Nucleic acids encoding g protein-coupled receptors
WO2002042482A3 (en) Functional lentiviral vector from an mlv-based backbone
WO2003004055A3 (en) Nucleic acid adjuvants
WO2000058352A3 (en) Barley gene for thioredoxin and nadp-thioredoxin reductase
EP1762613A3 (en) Insertion sequence elements derived from ralstonia solanacearum
WO2002081415A3 (en) Method for inhibiting metap2
WO2001068846A3 (en) Transcription activator of the cited family

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 152423

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002721113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002252061

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002568722

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 527730

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2439185

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2002721113

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642